CYP19A1 and breast carcinoma: The objective of this study is to evaluate the efficacy, safety, and adherence to Palbociclib in combination with either an aromatase inhibitor or fulvestrant in a real-world cohort of HR+/HER2− breast cancer patients from Romania.